A New Target for Allergy and Asthma Treatment

Eosinophils are a tissue dwelling hematopoietic cell type that likely play a role in parasitic immunity and allergic disease, such as asthma. Activated eosinophils secrete toxic basic proteins such as Major Basic Protein (MBP) which are postulated to cause bronchial hyper-reactivity, damage of the bronchial mucosa, and remodeling of the airways. Our inventorsat the University of Utah have identified a nested RNA gene that regulates human eosinophil development. They have been able to design a treatment method to inhibit Eosinophil development.

Benefits
Abolishing eosinophil development by developing a drug target could have considerable commercial application in eosinophil associated diseases such as asthma, hypereosinophilic syndrome, atopic dermatitis and drug reactions

Stage of Development
A provisional patent application has been filed with the U.S. Patent and Trademark Office and is pending. This technology is part of an active and ongoing research program and is available for developmental research support/licensing under either exclusive or non-exclusive terms.

Additional Info
*EGO, a novel, non-coding RNA gene, regulates eosinophil granule protein transcript expression. Blood, March 9, Epub (2007)
*http://uuhsc.utah.edu/derm/bios/facultybios/ggleich.htm

Inventor(s): Lori Wagner, Gerald Gleich

Type of Offer: Licensing



« More Medical Patents

---